Oxford BioMedica PLC (OXBDF)

[marcusl2]

OXB-302 (CAR-T 5T4)
• Pre-clinical studies completed, demonstrating proof-of-concept
• Highlights include:
• CAR-T 5T4 cells can kill tumour cells derived from colorectal cancer and mesothelioma in
a “test tube” (in vitro)
• T cells taken from patients with ovarian cancer can be re-programmed with the 5T4 CAR
construct and respond (in vitro) to their own tumour cells, resulting in tumour cell death
• In industry standard animal model (in vivo) 5T4 CAR-T cells can treat established ovarian cancer